Results 121 to 130 of about 30,638 (285)

Drug‐Related Engrams and Their Role in the Persistence and Recurrence of Drug‐Related Behaviors

open access: yesHippocampus, Volume 35, Issue 6, November 2025.
ABSTRACT Memory is a cornerstone of human behavior, and addiction offers a compelling model of its persistence and plasticity. The scope of engram research has rapidly expanded to include addiction‐related phenomena. Addiction‐related memories, like strong aversive memories, are often highly resistant to extinction and can continue to drive relapse ...
M. Cutler, A. Thati, S. L. Grella
wiley   +1 more source

Effects of a new opioid peptide (Tyr-Arg) on lamina V type neurons of the rabbit spinal dorsal horn

open access: gold, 1979
Masamichi Satoh   +3 more
openalex   +1 more source

Silver (I) and Silver (II) Oxide Films for Biomedical Implants: Synthesis, Stability, Ion Release, and Antibacterial Efficacy

open access: yesJournal of Biomedical Materials Research Part A, Volume 113, Issue 11, November 2025.
ABSTRACT Coatings of silver compounds with higher dissolution rates than metallic silver offer a promising approach for delivering Ag+ ions to prevent medical implant device‐associated infections. In this study, we investigate the synthesis and characterization of single‐phase, silver (I) oxide (Ag2O) and silver (II) oxide (AgO) for potential ...
Maxwell Akantibila   +12 more
wiley   +1 more source

Opioid peptide precursors in striatum [PDF]

open access: yesFEBS Letters, 1980
K.M. Metters   +3 more
openaire   +3 more sources

Evaluating biased agonism of glucagon‐like peptide‐1 (GLP‐1) receptors to improve cellular bioenergetics: A systematic review

open access: yesDiabetes, Obesity and Metabolism, Volume 27, Issue 11, Page 6105-6115, November 2025.
Abstract Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are highly effective antidiabetic and anti‐obesity agents. Recent development and optimisation of these agents includes biased agonism (selective activation of a downstream signalling pathway) of the GLP‐1 receptor, which has demonstrated greater weight‐lowering effects and improved insulin
Sabrina Wong   +4 more
wiley   +1 more source

Cardiovascular and kidney outcomes of GLP‐1 receptor agonists in adults with obesity: A target trial emulation study

open access: yesDiabetes, Obesity and Metabolism, Volume 27, Issue 11, Page 6527-6536, November 2025.
Abstract Aims Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) provide cardiovascular and renal benefits in type 2 diabetes, but their real‐world effects in individuals with obesity without diabetes are unclear. This study aimed to evaluate the cardiovascular and kidney outcomes of GLP‐1RAs versus other anti‐obesity medications (AOMs) in adults ...
Huilin Tang   +8 more
wiley   +1 more source

Sequence similarity between opioid peptide precursors and DNA‐binding proteins [PDF]

open access: bronze, 1991
Georgy Bakalkin   +3 more
openalex   +1 more source

Home - About - Disclaimer - Privacy